参考文献/References:
1 Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in comb ination with gemcitabine for advanced pancreatic cancer, a multicenter phase Ⅱ Trial. J Clin Oncol, 2004, 22(13):2610-2616.
2 Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol,2005, 23(15):3568-3576.
3 Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351(4):337-345.
4 Untch M, Eidtmann H, du Bois A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer:results of a phase Ⅰ trial.Eur J Cancer, 2004, 40(7):988-997.
5 Sledge GW Jr. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Williston Park), 2003, 17(12Suppl 14):33-35.
6 Osoba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol, 2002, 20(14):3106-3113.
7 Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol, 2004, 22(15):3003-3015.
8 Vanhoefer U, Tewes M, Rojo F, et al. Phase Ⅰ study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol, 2004, 22(1):175-184.
9 Crombet T, Osorio M, Cruz T, et al. Use of the humanized antiepidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients, J Clin Oncol,2004, 22(9):. 1646-1654.
10 Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional phase Ⅱ trial of gefitinib for previously treated patients with advance non-small-cell lung cancer. J Clin Oncol, 2003, 21(12):2237-2246.
11 Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib(ZD1839, IressaTM), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer:a randomized trial. J Am Med Assoc, 2003, 290(16):2149-2158.
12 Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT 1. J Clin Oncol, 2004, 22(5):777-784.
13 Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT 2..J Clin Oncol, 2004, 22(5):785-794.
14 Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 2004, 22(1):77-85.
15 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med,2005, 353(2):123-132.
16 Bence AK, Anderson EB, Halepota MA, et al. Phase Ⅰ pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.Invest New Drugs, 2005, 23(1):39-49.
17 Calvo E, Tolcher AW, Hammond LA, et al. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule:a phase Ⅰ pharmacok-inetic and food effect study. Clin Cancer Res, 2004, 10(21):7112-7120.
18 Meenakshi A, Ganesh V, Suresh Kumar R, et al. Radioimmuno targetting (99m)technetium labeled anti-epidermal growth factor receptor monoclonal antibodies in experimental tumor models. Q J Nucl Med, 2003, 47(2):139-144.
19 Tang Y, Wang J, Scollard DA, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Hereeptin)Fab fragments. Nucl Med Biol, 2005,32(1):51-58.
20 Mishani E, Abourbeh G, Rozen Y, et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid[4-(phenylamino)-quinazoline-6-yl]-amides:potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol, 2004, 31(4):469-476.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[3]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[4]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[5]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[6]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[7]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[8]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[9]黄丽娟,陈宁,叶静,等.反义肽核酸对促甲状腺激素受体mRNA表达的影响[J].国际放射医学核医学杂志,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
HUANG Li-juan,CHEN Ning,YE Jing,et al.The effects of antisense peptide nucleic acid on the expression of thyroid stimulating hormone receptor mRNA[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
[10]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[11]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[12]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[13]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[14]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[15]王相成,王雪梅,何玉林,等.PET-CT表皮生长因子受体显像的研究进展[J].国际放射医学核医学杂志,2010,34(5):266.[doi:10.3760/cma.j.issn.1673-4114.2010.05.003]
WANG Xiang-cheng,WANG Xue-mei,HE Yu-lin,et al.Study progress of PET-CT epidermal growth factor receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):266.[doi:10.3760/cma.j.issn.1673-4114.2010.05.003]
[16]汪永红,陈文新,何品玉.肿瘤表皮生长因子受体的分子显像研究[J].国际放射医学核医学杂志,2009,33(4):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
WANG Yong-hong,CHEN Wen-xin,HE Pin-yu.Tumor epidermal growth factor receptor molecular imaging research[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
[17]黄顺,韩彦江,郑希,等.靶向表皮生长因子受体小分子类PET显像剂研究进展[J].国际放射医学核医学杂志,2017,41(1):50.[doi:10.3760/cma.j.issn.1673-4114.2017.01.010]
Huang Shun,Han Yanjiang,Zheng Xi,et al.PET imaging agents of small molecules inhibitors targeting EGFR[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):50.[doi:10.3760/cma.j.issn.1673-4114.2017.01.010]
[18]袁卫红,罗志航,彭荣宗,等.肺癌与表皮生长因子及其受体关系的研究[J].国际放射医学核医学杂志,2006,30(5):261.
YUAN Wei-hong,LUO Zhi-hang,PENG Rong-zong,et al.The study on the correlation between EGF, EGFR and lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):261.
[19]何蕊,朱高红.甲状腺髓样癌靶向治疗的研究进展[J].国际放射医学核医学杂志,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]
He Rui,Zhu Gaohong.Research status of medullary thyroid carcinoma targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]